新股消息 | 科郦有限公司递表港交所 为综合医疗健康解决方案供应商

Company Overview - 科郦有限公司 is a comprehensive healthcare solution provider originating from South Korea, primarily operating in China and expanding internationally. The company focuses on upgrading the pharmaceutical supply chain through digital solutions and promoting innovation in the biopharmaceutical and multifunctional nutrition sectors [4]. - The company ranks among the top ten in China's pharmaceutical marketing, promotion, and sales market by revenue for 2024, and is the largest provider of pediatric pharmaceutical marketing and sales services in China, holding approximately 15.9% market share [4]. Business Operations - The company operates a sales network covering all 31 provinces in mainland China, including major cities and has over 1,500 distributors, reaching around 110,000 clinics, 310,000 pharmacies, and 3,600 hospitals, including 68 Class III hospitals [4]. - The main business lines include pharmaceutical marketing, promotion, and sales, as well as the research, production, and distribution of maternal and infant nutritional supplements [5]. Financial Performance - The company reported revenues of $322 million, $350 million, $282 million, and $143 million for the fiscal years ending December 31, 2022, 2023, 2024, and the six months ending June 30, 2025, respectively [6]. - The profit figures for the same periods were $17.34 million, $24.77 million, $21.85 million, and $21.83 million [6]. Profitability Metrics - The gross profit margins for the company were 43.6%, 48.3%, 53.3%, and 56% for the fiscal years ending December 31, 2022, 2023, 2024, and the six months ending June 30, 2025, respectively [8]. - The net profit margins were 5.4%, 7.1%, 7.7%, and 15.1% for the same periods [9]. Industry Overview - The Chinese pharmaceutical industry is projected to grow from RMB 1,447.9 billion in 2020 to RMB 1,629.7 billion by 2024, with a compound annual growth rate (CAGR) of 4.0%, reaching RMB 1,985.4 billion by 2029 [10]. - The pediatric pharmaceutical market is expected to grow at a CAGR of 5.0%, reaching RMB 123.2 billion by 2029 [13]. - The pharmaceutical marketing, promotion, and sales industry in China is projected to reach RMB 139 billion by 2029, with a CAGR of 7.3% from 2024 [17]. Market Trends - The pediatric pharmaceutical marketing and sales sector is expected to grow from RMB 6.4 billion in 2020 to RMB 9.6 billion by 2024, with a CAGR of 10.7%, and is projected to reach RMB 14.8 billion by 2029 [20]. - The probiotics supplement market in China is anticipated to grow from RMB 17.2 billion in 2020 to RMB 24.6 billion by 2024, with a CAGR of 9.4%, and is expected to reach RMB 40 billion by 2029 [22].